Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1641 1677 1678 1758 1787
This examiner grants 59% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18096464 | METHODS OF ASSESSING RISK OF AND TREATING PREECLAMPSIA AND SUBTYPES THEREOF | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 17904873 | SYSTEMS AND METHODS FOR DETECTION OF ANALYTES | Non-Final OA | The Texas A&M University System |
| 18279624 | BIOMARKER | Non-Final OA | Oxford University Innovation Limited |
| 18474826 | BIOMARKERS AND METHODS FOR DIFFERENTIATING BETWEEN MILD AND SUPERMILD TRAUMATIC BRAIN INJURY | Non-Final OA | Abbott Laboratories |
| 17595478 | REAGENTS FOR SANDWICH IMMUNOASSAYS USING PARTICLE ENHANCED AGGLUTINATION DETECTION AND METHODS OF PRODUCTION AND USE THEREOF | Final Rejection | Siemens Healthcare Diagnostics Inc. |
| 18158768 | Biomarkers for identifying e-cigarette, or vaping, product use-associated lung injury | Non-Final OA | University of Rochester |
| 18561621 | sFRP4 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ADENOMYOSIS | Non-Final OA | Roche Diagnostics Operations, Inc. |
| 17821951 | TnT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION | Final Rejection | Roche Diagnostics Operations, Inc. |
| 17772959 | SEPSIS MANAGEMENT | Non-Final OA | ROCHE DIAGNOSTICS OPERATIONS, INC. |
| 18557941 | Biomarkers for Neurodegenerative Disease | Non-Final OA | Yeda Research and Development Co. Ltd. |
| 18257697 | USE OF ALARMINS AS BIOMARKERS FOR ASSESSING ISCHEMIA-REPERFUSION INJURY SEVERITY AFTER SOLID ORGAN TRANSPLANTATION | Non-Final OA | UNIVERSITE DE POITIERS |
| 17602757 | A METHOD FOR DETERMINING THE LIKELIHOOD OF A PATIENT BEING RESPONSIVE TO CANCER IMMUNOTHERAPY | Non-Final OA | UNIVERSITÄT ZÜRICH |
| 18551454 | DIAGNOSIS OF ALZHEIMER'S DISEASE BY DETECTING AUTO-ANTIBODIES AGAINST Y-BOX BINDING PROTEIN-1 (YB-1) | Non-Final OA | CELLTREND GMBH |
| 18243034 | RAPID QUANTITATIVE ASSAY TO ASSESS DURATION OF INFECTION | Non-Final OA | SEDIA BIOSCIENCES CORPORATION |
| 18033222 | METHODS FOR IDENTIFYING AND TREATING ANTIBODY-MEDIATED ACQUIRED PRIMARY OR RECURRENT IDIOPATHIC NEPHROTIC SYNDROME | Non-Final OA | Boston Medical Center Corporation |
| 18276218 | MARKER FOR DIAGNOSIS OF NONALCOHOLIC FATTY LIVER DISEASE | Non-Final OA | BREXOGEN INC. |
| 18155299 | Methods for Middle Down Antibody Characterization | Non-Final OA | Universiteit Utrecht Holding B.V. |
| 18256453 | USE OF THE EMM ANTIGEN AS A BIOMARKER OF INHERITED GPI DEFICIENCIES | Non-Final OA | ETABLISSEMENT FRAN¿AIS DU SANG (EFS) |
| 18037592 | BIOMARKERS FOR PREDICTING IMMUNOGENICITY AND THERAPEUTIC RESPONSES TO ADALIMUMAB IN RHEUMATOID ARTHRITIS PATIENTS | Non-Final OA | CHINA MEDICAL UNIVERSITY HOSPITAL |
| 18194151 | Pregnancy clock proteins for predicting due date and time to birth | Final Rejection | Sera Prognostics, Inc. |
| 18016384 | METHOD FOR DETERMINING WHETHER A SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENT IS UNDERGOING A PRE-FLARE EVENT | Non-Final OA | Oklahoma Medical Research Foundation |
| 18092290 | Compositions, Devices, and Methods For Performing Agglutination Assays | Final Rejection | Nanospot.ai, Inc. |
| 17635265 | A METHOD FOR DIAGNOSING OR MONITORING KIDNEY FUNCTION OR DIAGNOSING KIDNEY DYSFUNCTION IN PEDIATRIC PATIENTS | Non-Final OA | SPHINGOTEC GMBH |
| 17131008 | METHOD FOR PREDICTING THE RISK OF GETTING CANCER OR DIAGNOSING CANCER IN A FEMALE SUBJECT | Non-Final OA | SPHINGOTEC GMBH |
| 15382367 | SYSTEMS AND METHODS FOR POINT-OF-CARE HDL AND LDL PARTICLE ASSAY | Non-Final OA | Polymer Technology Systems, Inc. |
| 17627904 | ANTIBODY SPECIFICALLY BINDING TO WRS PROTEIN, AND USE THEREOF | Non-Final OA | CUREBIO THERAPEUTICS. CO., LTD. |
| 17595830 | COMPANION DIAGNOSTIC ASSAY FOR GLOBO-H RELATED CANCER THERAPY | Non-Final OA | Ming-Tain LAI |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy